Immuno-Biological Laboratories Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Immuno-Biological Laboratories has a total shareholder equity of ¥1.3B and total debt of ¥239.0M, which brings its debt-to-equity ratio to 18.2%. Its total assets and total liabilities are ¥1.7B and ¥370.0M respectively. Immuno-Biological Laboratories's EBIT is ¥155.0M making its interest coverage ratio 155. It has cash and short-term investments of ¥763.0M.
Anahtar bilgiler
18.2%
Borç/özkaynak oranı
JP¥239.00m
Borç
| Faiz karşılama oranı | 155x |
| Nakit | JP¥763.00m |
| Eşitlik | JP¥1.32b |
| Toplam yükümlülükler | JP¥370.00m |
| Toplam varlıklar | JP¥1.69b |
Son finansal sağlık güncellemeleri
Immuno-Biological Laboratories (TSE:4570) Seems To Use Debt Rather Sparingly
Aug 03
We Think Immuno-Biological Laboratories (TSE:4570) Can Manage Its Debt With Ease
Feb 29Is Immuno-Biological Laboratories (TYO:4570) Using Debt In A Risky Way?
Feb 09Recent updates
Immuno-Biological Laboratories (TSE:4570) Seems To Use Debt Rather Sparingly
Aug 03Investors Shouldn't Be Too Comfortable With Immuno-Biological Laboratories' (TSE:4570) Earnings
May 22We Think Immuno-Biological Laboratories (TSE:4570) Can Manage Its Debt With Ease
Feb 29Is Immuno-Biological Laboratories (TYO:4570) Using Debt In A Risky Way?
Feb 09Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 4570's short term assets (¥1.3B) exceed its short term liabilities (¥277.0M).
Uzun Vadeli Yükümlülükler: 4570's short term assets (¥1.3B) exceed its long term liabilities (¥93.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 4570 has more cash than its total debt.
Borcun Azaltılması: 4570's debt to equity ratio has reduced from 31.4% to 18.2% over the past 5 years.
Borç Kapsamı: 4570's debt is well covered by operating cash flow (55.6%).
Faiz Kapsamı: 4570's interest payments on its debt are well covered by EBIT (155x coverage).